Zylö Therapeutics licensed an innovative topical drug delivery system in 2017. The system, based on silica-derived microparticles called Z-pods®, held the promise of enhancing the bioavailability of many topically applied active ingredients (AIs) for animals, plants, and humans. Zylö has advanced the technology and readied it for commercialization.
Primary Application Area: Biotech, Pharma, Health
Technology Development Status: Ready to Market
Technology Readiness Level: TRL 7
Vetted Programs/Awards: Per Technology Summary above, Zylö has been awarded multiple Phase I and Phase II SBIR grants by NIH to further develop and commercialize the Z-pod® technology. Zylö is also a partner on a Department of Defense grant related to wound healing per above.
Organization Type: Small to Medium Enterprise
Market Keywords: topical application, bioavailability, erectile dysfunction, lupus, nail fungus, wound healing